Date: November 6, 2019
Hosted by: brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium on Neurodegeneration in Aging (CCNA).
Presented by: Krista L. Lanctôt, PhD, Director, Neuropsychopharmacology; Senior Scientist, Sunnybrook Research Institute; Professor of Psychiatry and Pharmacology, Vice-Chair, Basic and Clinical Science, Department of Psychiatry, University of Toronto
There is increasing interest in the use of cannabinoids as a therapeutic intervention in dementia, particularly for agitation.
By the end of this presentation learners will be aware that:
• agitation is a common and persistent symptom in those with Alzheimer’s disease
• current pharmacotherapies have modest efficacy and/or poor safety
• there is a pharmacologic rationale for use of cannabinoids
• limited literature has evaluated the efficacy of THC and related compounds for agitation
• a pilot study of a cannabinoid for agitation has recently been completed
This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium on Neurodegeneration in Aging (CCNA).